Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Trevi Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

COMPLETED FOLLOW-ON COMMON STOCK OFFERING WITH NET PROCEEDS OF ~$162 MILLION, EXTENDING EXPECTED CASH RUNWAY INTO 2030 THROUGH POTENTIAL FDA APPROVAL OF HADUVIO IN IPF-RELATED CHRONIC COUGH AND CONTINUED PIPELINE ADVANCEMENT CLINICAL DEVELOPMENT PLANS REMAIN ON TRACK ACROSS ALL CHRONIC COUGH INDICATIONS MANAGEMENT TO HOST A CONFERENCE CALL AND WEBCAST TODAY AT 4:30 P.M. ET NEW HAVEN, CONN.

TREVI THERAPEUTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

PRIMARY AND SUBGROUP ANALYSIS FROM THE PHASE 2B CORAL TRIAL OF NALBUPHINE ER FOR THE TREATMENT OF PATIENTS WITH IPF-RELATED CHRONIC COUGH ACCEPTED FOR ORAL PRESENTATION, INCLUDING KEY SUBGROUP ANALYSES BY BASELINE COUGH COUNT AND BACKGROUND ANTI-FIBROTIC USE AN EXPLORATORY POST-HOC ANALYSIS OF THE EFFECTS OF NALBUPHINE ER AND PLACEBO ON COUGH BOUTS FROM THE PHASE 2B CORAL TRIAL IN PATIENTS WITH IPF-RELATED CHRONIC COUGH AND THE PHASE 2A RIVER TRIAL IN PATIENTS WITH REFRACTORY CHRONIC COUGH DRUGDRUG INTERACTION DATA FROM A PHASE 1 STUDY EVALUATING PHARMACOKINETICS AND SAFETY FOLLOWING CO-ADMINISTRATION OF NALBUPHINE ER WITH PIRFENIDONE OR NINTEDANIB NEW HAVEN, CONN., APRIL 30, 2026 (GLOBE NEWSWIRE) -- TREVI THERAPEUTICS, INC. (NASDAQ: TRVI),A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING THE INVESTIGATIONALTHERAPYORAL NALBUPHINE ER FOR THE TREATMENT OF CHRONIC COUGH IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF), NON-IPF INTERSTITIAL LUNG DISEASE (NON-IPF ILD),AND REFRACTORY CHRONIC COUGH (RCC),TODAY ANNOUNCED THAT IT WILL DELIVER AN ORAL PRESENTATION AND PRESENT MULTIPLE ABSTRACTS AT THE AMERICAN THORACIC SOCIETY (ATS) 2026 INTERNATIONAL CONFERENCE, TAKING PLACE FROM MAY 15  20, 2026, IN ORLANDO, FLORIDA.

TREVI THERAPEUTICS ANNOUNCES ORAL PRESENTATION AND MULTIPLE POSTERS ACCEPTED AT THE AMERICAN THORACIC SOCIETY (ATS) 2026 INTERNATIONAL CONFERENCE

NEW HAVEN, CONN., APRIL 28, 2026 (GLOBE NEWSWIRE) -- TREVI THERAPEUTICS, INC. (NASDAQ: TRVI), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING THE INVESTIGATIONALTHERAPYHADUVIO(ORAL NALBUPHINE ER)FOR THE TREATMENT OF CHRONIC COUGH IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF), NON-IPF INTERSTITIAL LUNG DISEASE (NON-IPF ILD),AND REFRACTORY CHRONIC COUGH (RCC), TODAY ANNOUNCED THAT SENIOR MANAGEMENT WILL HOST A CONFERENCE CALL AND LIVE AUDIO WEBCAST ON TUESDAY, MAY 5, 2026, AT 4:30 P.M.

TREVI THERAPEUTICS TO REPORT FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE ON MAY 5, 2026

NEW HAVEN, CONN., APRIL 23, 2026 (GLOBE NEWSWIRE) -- TREVI THERAPEUTICS, INC. (NASDAQ: TRVI),A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING THE INVESTIGATIONALTHERAPYHADUVIO(ORAL NALBUPHINE ER)FOR THE TREATMENT OF CHRONIC COUGH IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF), NON-IPF INTERSTITIAL LUNG DISEASE (NON-IPF ILD),AND REFRACTORY CHRONIC COUGH (RCC), TODAY ANNOUNCED THAT SENIOR MANAGEMENT WILL PARTICIPATE IN SEVERAL UPCOMING EVENTS IN MAY.

TREVI THERAPEUTICS TO PARTICIPATE IN UPCOMING MAY EVENTS

NEW HAVEN, CONN., APRIL 20, 2026 (GLOBE NEWSWIRE) -- TREVI THERAPEUTICS, INC. (NASDAQ: TRVI), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING THE INVESTIGATIONAL THERAPY HADUVIO (ORAL NALBUPHINE ER) FOR THE TREATMENT OF CHRONIC COUGH IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF), NON-IPF INTERSTITIAL LUNG DISEASE (NON-IPF ILD), AND REFRACTORY CHRONIC COUGH (RCC), TODAY ANNOUNCED THE CLOSING OF ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING OF 13,340,000 SHARES OF ITS COMMON STOCK AT A PUBLIC OFFERING PRICE OF $13.00 PER SHARE, WHICH INCLUDES 1,740,000 ADDITIONAL SHARES ISSUED UPON THE EXERCISE IN FULL BY THE UNDERWRITERS OF THEIR OPTION TO PURCHASE ADDITIONAL SHARES OF COMMON STOCK IN THE PUBLIC OFFERING AT THE PUBLIC OFFERING PRICE, LESS UNDERWRITING DISCOUNTS AND COMMISSIONS. THE TOTAL PROCEEDS OF THE PUBLIC OFFERING WERE APPROXIMATELY $173 MILLION, BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND EXPENSES PAYABLE BY TREVI. ALL OF THE SHARES IN THE OFFERING WERE SOLD BY TREVI.

TREVI THERAPEUTICS ANNOUNCES CLOSING OF $173 MILLION UNDERWRITTEN OFFERING AND FULL EXERCISE BY UNDERWRITERS OF OPTION TO PURCHASE ADDITIONAL SHARES

NEW HAVEN, CONN., APRIL 16, 2026 (GLOBE NEWSWIRE) -- TREVI THERAPEUTICS, INC. (NASDAQ: TRVI), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING THE INVESTIGATIONAL THERAPY HADUVIO (ORAL NALBUPHINE ER) FOR THE TREATMENT OF CHRONIC COUGH IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF), NON-IPF INTERSTITIAL LUNG DISEASE (NON-IPF ILD), AND REFRACTORY CHRONIC COUGH (RCC), TODAY ANNOUNCED THE PRICING OF ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING OF 11,600,000 SHARES OF ITS COMMON STOCK AT A PUBLIC OFFERING PRICE OF $13.00PER SHARE, FOR TOTAL PROCEEDS OF APPROXIMATELY $150 MILLION, BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND EXPENSES PAYABLE BY TREVI. ALL OF THE SHARES IN THE OFFERING ARE BEING SOLD BY TREVI. IN ADDITION, TREVI HAS GRANTED THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO 1,740,000ADDITIONAL SHARES OF ITS COMMON STOCK AT THE PUBLIC OFFERING PRICE, LESS UNDERWRITING DISCOUNTS AND COMMISSIONS. THE OFFERING IS EXPECTED TO CLOSE ON OR ABOUT APRIL 20, 2026, SUBJECT TO SATISFACTION OF CUSTOMARY CLOSING CONDITIONS.

TREVI THERAPEUTICS ANNOUNCES PRICING OF $150 MILLION UNDERWRITTEN OFFERING OF COMMON STOCK

NEW HAVEN, CONN., APRIL 16, 2026 (GLOBE NEWSWIRE) -- TREVI THERAPEUTICS, INC. (NASDAQ: TRVI), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING THE INVESTIGATIONAL THERAPY HADUVIO (ORAL NALBUPHINE ER) FOR THE TREATMENT OF CHRONIC COUGH IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF), NON-IPF INTERSTITIAL LUNG DISEASE (NON-IPF ILD), AND REFRACTORY CHRONIC COUGH (RCC), TODAY ANNOUNCED THAT IT HAS COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF $150,000,000 OF SHARES OF ITS COMMON STOCK. ALL OF THE SHARES IN THE OFFERING ARE BEING OFFERED BY TREVI. IN ADDITION, TREVI EXPECTS TO GRANT THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL $22,500,000 OF THE SHARES OF ITS COMMON STOCK SOLD IN THE PUBLIC OFFERING AT THE PUBLIC OFFERING PRICE, LESS UNDERWRITING DISCOUNTS AND COMMISSIONS.

TREVI THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

NEW HAVEN, CONN., APRIL 01, 2026 (GLOBE NEWSWIRE) -- TREVI THERAPEUTICS, INC. (NASDAQ: TRVI), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING THE INVESTIGATIONAL THERAPY HADUVIO (ORAL NALBUPHINE ER) FOR THE TREATMENT OF CHRONIC COUGH IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF), NON-IPF INTERSTITIAL LUNG DISEASE (NON-IPF ILD), AND REFRACTORY CHRONIC COUGH (RCC), TODAY ANNOUNCED THAT SENIOR MANAGEMENT WILL BE PARTICIPATING IN THE FOLLOWING EVENTS.

TREVI THERAPEUTICS TO PARTICIPATE IN UPCOMING EVENTS

FOLLOWING THE END-OF-PHASE 2 MEETING WITH THE FDA, THE COMPANY GAINED ALIGNMENT ON ITS PHASE 3 PROGRAM FOR THE TREATMENT OF PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS-RELATED CHRONIC COUGH

TREVI THERAPEUTICS REPORTS FOURTH QUARTER AND YEAR END 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

NEW HAVEN, CONN., MARCH 10, 2026 (GLOBE NEWSWIRE) -- TREVI THERAPEUTICS, INC. (NASDAQ: TRVI), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING THE INVESTIGATIONALTHERAPYHADUVIO(ORAL NALBUPHINE ER)FOR THE TREATMENT OF CHRONIC COUGH IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF), NON-IPF INTERSTITIAL LUNG DISEASE (NON-IPF ILD),AND REFRACTORY CHRONIC COUGH (RCC), TODAY ANNOUNCED THAT SENIOR MANAGEMENT WILL HOST A CONFERENCE CALL AND LIVE AUDIO WEBCAST ON TUESDAY, MARCH 17, 2026, AT 4:30 P.M.

Trevi Therapeutics, Inc.

TRVI

Price

Financial Reports

No items found.

Press Releases

Trevi Therapeutics, Inc.

TRVI.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

TRVI